Skip to main content

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting · Phase 4 · NCT06112743

Conditions: Cardiomyopathy, Hypertrophic

At a glance

Research payments reported, 2025
$167,352
U.S. investigators named
8
Sites paid
11
Planned or actual enrollment
63

About the trial

Sponsor
Bristol-Myers Squibb
Tested
Mavacamten (drug)
Dates
Started 2024-01-24; completion 2027-06-10
Results posted
Not yet

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].

From ClinicalTrials.gov, last updated 2026-09-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $167,352 in research payments for this study in 2025 (12 payments).

Products named: Camzyos

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.